Replies to post #18347 on Ayala Pharmaceuticals Inc (ADXS)

[Meishairwin]

Polaco3us, I did look at the table with both dose cohorts. A sample 3 three patients for the 2-dose cohort is too small to be very confident in the better response than the 1-dose cohort. I do believe ADXS has something there with AXAL, but no one should be convinced AXAL will blow the doors off a randomized SOC control arm. I hope it does -- I'm invested on that belief -- but I'm just trying to caution anyone who thinks AXAL is a slam-dunk. It's not.